A phase 1/2 clinical trial of KB103 for Dystrophic Epidermolysis Bullosa (DEB)

Trial Profile

A phase 1/2 clinical trial of KB103 for Dystrophic Epidermolysis Bullosa (DEB)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs KB 103 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Krystal Biotech
  • Most Recent Events

    • 20 Nov 2017 New trial record
    • 13 Nov 2017 According to a Krystal Biotech media release, this study protocol has received clearance from the Recombinant DNA Advisory Committee (RAC) in the last week for treating Dystrophic Epidermolysis Bullosa (DEB). Also, company is currently preparing to file an IND for KB103 in the Q12018 and plans to initiate the trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top